Compare RBBN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | FHTX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.8M | 360.5M |
| IPO Year | 2017 | 2020 |
| Metric | RBBN | FHTX |
|---|---|---|
| Price | $2.12 | $6.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.67 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 807.6K | 213.2K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $1.97 | $8.89 |
| Revenue Next Year | $6.69 | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.83 | $3.27 |
| 52 Week High | $4.24 | $6.95 |
| Indicator | RBBN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 61.43 |
| Support Level | $2.06 | $5.22 |
| Resistance Level | $2.30 | $5.88 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 35.62 | 99.15 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.